Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine M Heske

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|February 4, 2020
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer TherapyChristine M Heske
Journal of Clinical Medicine|March 6, 2021
Relapsed RhabdomyosarcomaChristine M Heske, Leo Mascarenhas
Current Opinion in Pediatrics|December 3, 2019
Targeting metabolic dependencies in pediatric cancerSameer H Issaq, Christine M Heske
Cancer Drug Resistance (Alhambra, Calif.)|May 9, 2025
Mechanisms of resistance to NAMPT inhibitors in cancerJansen Redler, Ariana E Nelson, Christine M Heske
Cancers|May 11, 2024
Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for ImmunotherapySophia J Zhao, Daniel Prior, Christine M Heske, et al.
Cancer Medicine|April 21, 2023
Impact of race and ethnicity on presentation and outcomes of patients treated on rhabdomyosarcoma clinical trials: A report from the Children's Oncology GroupSenna R Munnikhuysen, Princess A Ekpo, Wei Xue, et al.
Translational Oncology|November 12, 2016
The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of RhabdomyosarcomaChristine M Heske, Choh Yeung, Arnulfo Mendoza, et al.
Oncogenesis|September 10, 2020
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcomaAnna E Gibson, Choh Yeung, Sameer H Issaq, et al.
Cancer|November 20, 2020
Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupChristine M Heske, Yueh-Yun Chi, Rajkumar Venkatramani, et al.
Oncotarget|September 10, 2016
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcomaChristine M Heske, Arnulfo Mendoza, Leah D Edessa, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|February 4, 2020
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer TherapyChristine M Heske
Journal of Clinical Medicine|March 6, 2021
Relapsed RhabdomyosarcomaChristine M Heske, Leo Mascarenhas
Current Opinion in Pediatrics|December 3, 2019
Targeting metabolic dependencies in pediatric cancerSameer H Issaq, Christine M Heske
Cancer Drug Resistance (Alhambra, Calif.)|May 9, 2025
Mechanisms of resistance to NAMPT inhibitors in cancerJansen Redler, Ariana E Nelson, Christine M Heske
Cancers|May 11, 2024
Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for ImmunotherapySophia J Zhao, Daniel Prior, Christine M Heske, et al.
Cancer Medicine|April 21, 2023
Impact of race and ethnicity on presentation and outcomes of patients treated on rhabdomyosarcoma clinical trials: A report from the Children's Oncology GroupSenna R Munnikhuysen, Princess A Ekpo, Wei Xue, et al.
Translational Oncology|November 12, 2016
The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of RhabdomyosarcomaChristine M Heske, Choh Yeung, Arnulfo Mendoza, et al.
Oncogenesis|September 10, 2020
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcomaAnna E Gibson, Choh Yeung, Sameer H Issaq, et al.
Cancer|November 20, 2020
Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupChristine M Heske, Yueh-Yun Chi, Rajkumar Venkatramani, et al.
Oncotarget|September 10, 2016
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcomaChristine M Heske, Arnulfo Mendoza, Leah D Edessa, et al.
Pageof 4